Printer Friendly

ICN PHARMACEUTICALS OPENS NEW SPANISH PLANT AS PART OF EUROPEAN EXPANSION

 ICN PHARMACEUTICALS OPENS NEW SPANISH PLANT
 AS PART OF EUROPEAN EXPANSION
 BARCELONA, Spain, March 17 /PRNewswire/ -- ICN Hubber, a unit of America's ICN Pharmaceuticals Inc. (NYSE: ICN), officially opened today a new $17 million (U.S.) state-of-the-art pharmaceutical manufacturing plant in Barcelona in a further step in the company's expanding European operations.
 The dedication of the site was presided by Xavier Trias, Health Minister of the Catalan regional government, and Milan Panic, founder, chairman and chief executive officer of ICN and its SPI Pharmaceuticals subsidiary, of which ICN Hubber is a part. The plant, which has been built and equipped to meet GMP (Good Manufacturing Practices) standards, is located in Corbera de Llobregat, Spain, 20 miles south of Barcelona, Spain's second-largest city.
 In remarks during the ceremony, Panic singled out the investment in ICN's Spanish operation as "a major strategic step in expanding our European presence." ICN, through SPI, operates another plant in Holland and recently moved into Eastern Europe with the formation of a new venture company, ICN Galenika of Yugoslavia.
 ICN Hubber was established in Spain as the result of the 1987 acquisition of Barcelona-based Hubber Laboratories. Spanish sales in 1990 were $26 million (U.S.). The new plant will permit a significant increase in activity in the Spanish pharmaceutical market, as well as throughout other Western and Eastern Europe pharmaceutical markets.
 ICN Pharmaceuticals is comprised of three subsidiaries: SPI Pharmaceuticals (AMEX: SPI), ICN Biomedicals Inc. and Viratek Inc. (NASDAQ: VIRA). SPI makes, markets and distributes 600 prescription and nonprescription pharmaceuticals in more than 60 countries. Apart from its Spanish, United States and Eastern European operations, SPI also serves international markets from major operations in Canada and Mexico.
 -0- 3/17/92
 /CONTACT: Paul Knopick of ICN Pharmaceuticals, 714-545-0100, ext. 2465/
 (ICN) CO: ICN Hubber; ICN Pharmaceuticals ST: California IN: MTC SU:


EH-JL -- LA020 -- 8854 03/17/92 15:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1992
Words:313
Previous Article:INDEPENDENT BANK CORPORATION INCREASES DIVIDEND BY 13 PERCENT
Next Article:EWING M. KAUFFMAN, CHAIRMAN EMERITUS, MARION MERRELL DOW INC., TO BE INDUCTED INTO 1992 NATIONAL SALES HALL OF FAME
Topics:


Related Articles
CAPITALISM WINNING IN EASTERN EUROPE; ICN YUGOSLAVIAN PHARMACEUTICAL WORKERS HAIL ANNIVERSARY
SPI PRESIDENT TELLS SPANISH TRADE DELEGATION COMPANY GROWTH LINKED TO EUROPEAN EXPANSION
ICN'S JERNEY SAYS COMPANY IS KEY PLAYER IN CAPITALISM'S REBIRTH IN EASTERN EUROPE
ICN PHARMACEUTICALS ACQUIRES MAJORITY STAKE IN RUSSIAN COMPANY; MOVE PAVES WAY FOR DISTRIBUTION OF NEW MEDICINES
ICN OPENS OFFICE IN MOSCOW; LIFTING OF ECONOMIC SANCTIONS ON YUGOSLAVIA MAKES EXPORTS TO RUSSIA POSSIBLE
ICN EXPANDS SALES FORCE IN LATIN AMERICA
DEMAND FOR MEDICINE CALLS FOR ICN EXPANSION IN RUSSIA; ICN TO LAUNCH PROZAC UNDER ITS OWN LABEL IN YUGOSLAVIA AND FORMER SOVIET UNION
ICN Finalizes Agreement to Acquire Hungarian Pharmaceutical Manufacturer
/C O R R E C T I O N -- ICN Pharmaceuticals/
ICN Pharmaceuticals Increases Worldwide Production With New Spanish Facility.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters